BIAF
bioAffinity Technologies, Inc. NASDAQ Listed Sep 1, 2022$0.84
+3.88%
vs $0.81
Mkt Cap $1.5M
52w Low $0.75
0.9% of range
52w High $10.95
50d MA $1.67
200d MA $2.08
P/E (TTM)
-0.1x
EV/EBITDA
—
P/B
0.2x
Debt/Equity
0.2x
ROE
-204.9%
P/FCF
-0.2x
RSI (14)
18.30
ATR (14)
$0.10
Beta
-0.81
50d MA
$1.67
200d MA
$2.08
Avg Volume
427.3K
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
22211 West Interstate 10 · San Antonio, TX 78257 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | AMC | -2.70 | -1.11 | +58.9% | 2.12 | -11.3% | -9.9% | +43.5% | -11.3% | +22.2% | -8.1% | — |
| Nov 14, 2025 | AMC | -2.70 | -2.70 | +0.0% | 1.84 | -6.0% | -14.1% | -7.0% | +0.0% | -6.1% | +6.5% | — |
| Aug 14, 2025 | AMC | -2.70 | -3.90 | -44.4% | 7.66 | -3.0% | -8.7% | +5.2% | +9.1% | -6.7% | -0.1% | — |
| May 15, 2025 | AMC | -0.16 | -0.16 | +0.0% | 6.17 | +1.0% | +2.9% | +6.3% | +29.8% | -3.1% | -2.7% | — |
| Mar 31, 2025 | AMC | -0.14 | -0.21 | -50.0% | 7.80 | +165.4% | +319.2% | -18.3% | -21.2% | -2.5% | +2.4% | — |
| Nov 14, 2024 | AMC | -0.15 | -0.16 | -6.7% | 39.90 | +0.8% | -1.5% | +2.3% | -0.7% | -4.5% | -2.4% | — |
| Aug 14, 2024 | AMC | -0.17 | -0.19 | -11.8% | 53.40 | +1.1% | -2.8% | +4.6% | -2.2% | -3.4% | +1.8% | — |
| May 15, 2024 | AMC | -0.15 | -0.21 | -40.0% | 56.40 | -0.5% | +30.3% | -7.8% | -1.8% | +6.8% | +4.6% | — |
| Apr 1, 2024 | AMC | -0.20 | -0.26 | -30.0% | 62.70 | +0.0% | +1.4% | +5.7% | +15.2% | +4.3% | -1.5% | — |
| Nov 14, 2023 | AMC | -0.18 | -0.26 | -44.4% | 43.23 | +0.6% | -1.8% | +1.1% | -2.8% | +3.6% | -2.1% | — |
| Aug 14, 2023 | AMC | -0.13 | -0.20 | -53.8% | 55.50 | -6.5% | +0.3% | -0.3% | -1.1% | -1.7% | +0.1% | — |
| May 15, 2023 | AMC | -0.21 | -0.18 | +14.3% | 54.60 | +0.0% | +1.6% | -2.7% | -1.1% | +2.8% | +3.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1 | Maxim Group | Downgrade | Buy → Hold | — | $7.80 | $20.70 | +165.4% | +319.2% | -18.3% | -21.2% | -2.5% | +2.4% |
No insider trades available.
8-K · 8.01
!! High
bioAffinity Technologies, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 30
8-K · 1.01
! Medium
bioAffinity Technologies, Inc. -- 8-K 1.01: Equity Issuance
Jun 18
8-K · 8.01
!! High
bioAffinity Technologies, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 16
8-K · 8.01
!! High
bioAffinity Technologies, Inc. -- 8-K 8.01: Material Event / Announcement
bioAffinity Technologies announced that the Society for Advanced Bronchoscopy will host a webinar promoting its CyPath Lung diagnostic tool for early-stage lung cancer detection and management across medical specialties.
Jun 2
8-K · 8.01
!! High
bioAffinity Technologies, Inc. -- 8-K 8.01: Material Event / Announcement
bioAffinity Technologies received Mexican patent allowance for its lung cancer prediction technology using flow cytometry, strengthening its intellectual property portfolio and potential competitive moat in diagnostic markets.
May 27
8-K · 8.01
!! High
bioAffinity Technologies, Inc. -- 8-K 8.01: Material Event / Announcement
May 12
8-K · 2.02
!! High
bioAffinity Technologies, Inc. -- 8-K 2.02: Earnings Results
bioAffinity Technologies reported Q1 2026 financial results, providing investors with operational performance metrics and financial condition updates for the quarter ending March 31, 2026.
May 8
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
BIAF released clinical evidence supporting CyPath Lung's diagnostic accuracy for lung cancer detection, potentially validating its noninvasive testing technology and strengthening market positioning.
Apr 14
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
BioAffiliates' CyPath Lung test gaining prominence at prestigious Cleveland Clinic symposium signals validation of its early cancer detection technology, potentially accelerating clinical adoption and revenue opportunities for investors.
Apr 7
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
bioAffinity's CyPath lung test unit sales jumped 146% YoY in Q1 2026, signaling strong market adoption of their noninvasive diagnostic technology and potential for accelerating revenue growth.
Apr 1
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Without access to the actual Regulation FD disclosure content in Exhibit 99.1, I cannot determine the specific announcement's impact on BIAF stock or provide meaningful investor guidance.
Mar 26
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
BioInfine Analytics' physician roundtable for its CyPath Lung diagnostic tool suggests emerging clinical adoption and potential revenue growth, making it worth monitoring for validation of their cancer detection technology's market traction.
Mar 25
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
BIAF released clinical evidence supporting CyPath Lung's diagnostic value in high-risk patients, potentially strengthening market adoption and justifying premium pricing for this noninvasive lung cancer test.
Mar 17
8-K
Unknown — 8-K Filing
BioAffinity Technologies issued a material press release on March 13, 2026, likely announcing significant business developments, clinical results, or partnership news that could substantially impact the stock's valuation and investor sentiment.
Mar 13
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
BIAF initiated a large-scale lung cancer screening study for its CyPath Lung diagnostic, potentially validating commercial viability and accelerating regulatory approval, which could significantly de-risk the stock.
Mar 10
8-K · 5.02
!!! Very High
bioAffinity Technologies, Inc. -- 8-K 5.02: Executive Change
The departure of an executive at bioAffinity Technologies raises concerns about leadership stability and strategic direction, potentially pressuring the stock if investors lose confidence in management's ability to execute on cancer diagnostic development.
Mar 6
8-K · 8.01
!! High
bioAffinity Technologies, Inc. -- 8-K 8.01: Material Event / Announcement
bioAffinity Technologies presented diagnostic research on sputum-based asthma treatment matching at the AAAAI 2026 conference, potentially advancing its clinical diagnostics platform for respiratory disease management.
Mar 3
8-K · 8.01
!! High
bioAffinity Technologies, Inc. -- 8-K 8.01: Material Event / Announcement
bioAffinity Technologies announced a new validation study with Brooke Army Medical Center to assess its CyPath Lung test for early lung cancer detection using sputum samples, potentially expanding clinical applications.
Feb 25
8-K · 8.01
!! High
bioAffinity Technologies, Inc. -- 8-K 8.01: Material Event / Announcement
bioAffinity Technologies released a clinical case study showing its CyPath Lung diagnostic tool successfully guided treatment decisions for a lung cancer patient, potentially validating the product's clinical utility for investors.
Feb 19
8-K · 8.01
!! High
bioAffinity Technologies, Inc. -- 8-K 8.01: Material Event / Announcement
bioAffinity Technologies released clinical case study data supporting CyPath Lung's utility in managing patients with multiple pulmonary nodules, potentially strengthening market positioning for its diagnostic platform.
Feb 17
8-K · 7.01
! Medium
bioAffinity Technologies, Inc. -- 8-K 7.01: Regulation FD Disclosure
bioAffinity Technologies posted updated presentation materials to its website, likely signaling management's effort to communicate operational updates and performance metrics to investors and stakeholders.
Feb 10
8-K · 8.01
!! High
bioAffinity Technologies, Inc. -- 8-K 8.01: Material Event / Announcement
bioAffinity Technologies appointed three physicians (David Ost, Daniel Sterman, and J. Scott Ferguson) to its Medical and Scientific Advisory Board, strengthening clinical credibility for its diagnostics platform.
Feb 9
8-K · 8.01
!! High
bioAffinity Technologies, Inc. -- 8-K 8.01: Material Event / Announcement
bioAffinity Technologies scheduled its 2026 Annual Meeting of Stockholders for April 30, 2026, in San Antonio, Texas, allowing investors to vote on corporate matters and board elections.
Feb 4
Institutional (13F) — Top 6
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 55,543 | $213K | New | Mar 2026 |
| 2 | Northern Trust Corp | 12,725 | $49K | — | Mar 2026 |
| 3 | Ubs Group Ag | 9,214 | $35K | New | Mar 2026 |
| 4 | Citigroup Inc | 7,741 | $9K | Added | Dec 2025 |
| 5 | Ifp Advisors, Inc | 833 | $3K | — | Mar 2026 |
| 6 | Morgan Stanley | 6 | $8 | — | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 4
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 29,770 | $32K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 4,398 | $5K | Feb 2026 |
| 3 | Fidelity Nasdaq Composite Index Fund | 601 | $637 | Feb 2026 |
| 4 | Fidelity Total Market Index Fund | 456 | $483 | Feb 2026 |
Valuation
Market Cap
$1.5M
Enterprise Value
-$4.2M
P/E (TTM)
-0.07x
Forward P/E
—
PEG Ratio
0.00x
P/B
0.20x
P/S
0.26x
P/FCF
-0.15x
EV/EBITDA
—
Shares Out
1.7M
Financials (TTM)
Revenue
$5.7M
Net Income
-$15.9M
EBITDA
-$15.3M
Free Cash Flow
-$9.4M
Op Cash Flow
-$9.3M
EPS Basic
$-8.66
EPS Diluted
$-12.44
EPS Forward
$-8.10
Gross Margin
22.1%
Op Margin
-204.3%
Net Margin
-280.6%
Balance Sheet
Total Assets
$11.0M
Total Liab.
$3.7M
Total Equity
$7.3M
Cash
$6.4M
LT Debt
$777K
Book Value/Sh
$4.23
Debt/Equity
0.16x
Current Ratio
2.60
Quick Ratio
2.58
Returns & Growth
ROE
-204.9%
ROA
-136.0%
ROIC
-125.3%
Rev Growth YoY
-34.2%
EPS Growth YoY
+61.5%
Price Returns
2W
-40.7%
1M
-53.6%
3M
-79.6%
6M
-33.4%
12M
-89.7%
Technicals
52W High
$10.95
52W Low
$0.75
50d MA
$1.67
200d MA
$2.08
RSI (14)
18.30
ATR (14)
$0.10
Beta
-0.81
Avg Volume
427K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 24, 2026 9:37pm
· Source: financialmodelingprep.com